ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,062.00
-0.10%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36125
0.00%
Bitcoin
67,011.05
0.11%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) News

VRDN

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRDN
DateTimeSourceHeadlineSymbolCompany
05/10/20247:00AMBusiness WireViridian Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
05/08/20246:51AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRDNViridian Therapeutics Inc
05/08/20246:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
05/08/20246:00AMBusiness WireViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
05/03/20247:00AMBusiness WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
04/29/20247:00AMBusiness WireViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VRDNViridian Therapeutics Inc
04/04/20243:01PMBusiness WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
03/06/20243:01PMBusiness WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
03/05/20247:00AMBusiness WireViridian Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:VRDNViridian Therapeutics Inc
02/28/20243:10PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRDNViridian Therapeutics Inc
02/27/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
02/27/20243:01PMBusiness WireViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
02/16/20247:00AMBusiness WireViridian Therapeutics Appoints Jennifer Tousignant as Chief Legal OfficerNASDAQ:VRDNViridian Therapeutics Inc
02/14/20247:28PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
02/14/20243:08PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
02/14/20243:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
02/14/20243:05PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
02/14/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
02/14/20248:01AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
02/07/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
02/06/20243:01PMBusiness WireViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
01/24/20245:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/24/20244:12PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
01/19/20244:22PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
01/19/20243:32PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
01/17/20249:00PMBusiness WireViridian Therapeutics Announces Pricing of Public Offering of Shares of Common StockNASDAQ:VRDNViridian Therapeutics Inc
01/17/20243:04PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
01/17/20243:01PMBusiness WireViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockNASDAQ:VRDNViridian Therapeutics Inc
01/12/20243:31PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/08/20247:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN

Your Recent History

LSE
XASX
X Msci Ukesg 1d
ASX
GCYDA
Gascoyne Resources
USOTC
BIOCQ
Biocept (CE)
NYSE
PANA.WS
Panacea Acquisition
DGFX
KAVAUSDT
Kava BEP2 Token
ASX
WMLOB
Woomera Mining
USOTC
MXGFF
Maxim Power (PK)
HUOB
KICKSUSDT
GetKicks
BIT
UI227B
Unicredit Bank
BIT
S29004
Societe Generale Effekten
COIN
EQUST
Equilibrium EQ Token
USOTC
KIIIW
Kismet Acquisition Three (CE)
LSE
OX71
Barclays 31
GATE
WAGYUUSDT
WAGYUSWAP.app
BIT
UB4QAP
Unicredit Bank
COIN
EZETH
EASY V2
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved